Precision Medicine in Inflammatory Bowel Disease Summit on January 30-February 01, 2023 in Boston, United States

With 10 million people worldwide living with IBD, there is an urgent need to move away from a one-size-fits-all standard of care and invest in the use of precision medicine to make informed decisions through patient selection and clinical monitoring, to reduce cost of care, prevent relapses and achieve long term remission.

Uniting experts across pharma, biotech and academia, the Precision Medicine in Inflammatory Bowel Disease Summit is your only dedicated forum to benchmark novel markers and innovative technology across RNA-sequencing, metabolomics, proteomics and more. Be involved in this cross-indication collaboration to translate basic immunology into clinical response and develop your biomarker strategy early.

Developed in collaboration with key industry thought leaders from AbbVie, Celsius Therapeutics, Crohn's and Colitis Foundation, Janssen, Prometheus Bioscience and more, leave this meeting with key lessons learned to improve your clinical trial efficacy, and patient care for those suffering with IBD.

URLs:

Website: https://go.evvnt.com/1382750-0?pid=10008

Tickets: https://go.evvnt.com/1382750-2?pid=10008

Brochure: https://go.evvnt.com/1382750-3?pid=10008

Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Academic Pricing - Conference + 2 Workshops: USD 3097.00,

Academic Pricing - Conference + 1 Workshop: USD 2648.00,

Academic Pricing - Conference Only: USD 2199.00,

Service Provider Pricing - Conference + 2 Workshops: USD 5097.00,

Service Provider Pricing - Conference + 1 Workshop: USD 4348.00,

Service Provider Pricing - Conference Only: USD 3599.00

Speakers: Heath Guay, Head of Immunology, Gastroenterology, Precision Medicine, AbbVie, Stephen Laroux, Scientific Director, Precision Medicine and Immunology, Abbvie, Dimitrios Iliopoulos, Chief Executive Officer, Athos Therapeutics, James Canavan, Executive Director - World Wide Medical Affairs, Bristol Myers Squibb, Rebecca Baker, Standards Developer, CDISC, Dave Evans, Chief Executive Officer, CDISC, Gerard Honig, Director - Autoimmunity and Inflammatory Bowel Disease, Celsius Therapeutics, Jeanne Magram, Chief Scientific Officer, Celsius Therapeutics, Angela Dobes, Vice President, IBD Plexus, Crohn's and Colitis Foundation of America, Andres Hurtado-Lorenzo, Vice President, Translational Research and IBD Ventures, Crohn's and Colitis Foundation, Mary Thanh Hai, Deputy Director for Clinical, Office of New Drugs, US Food and Drug Administration (FDA), Fiona Tamburini, Scientist, Genentech, Jean-Frederic Colombel, Professor - Medicine, Icahn Medical School Mount Sinai, Michael Dolinger, Assistant Professor Paediatric Gastroenterology, Mount Sinai, Jan Wehkamp, Vice President - Gastroenterology, Immunology Leadership Member and Global Disease Area Lead, Janssen, Matthew Jackson-Wood, Head of Precision Medicine, MiroBio, Ephraim Kenigsberg, Computational Scientist, Mount Sinai, Williams Turpin, Project Manager, GEM Project, Mount Sinai Canada, Olivier Laurent, Chief Scientific Officer, Prometheus Biosciences, Nicole Desch, Translational Biomarker Lead, Takeda

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development

Date and Time: 30th January 2023 at 9:00 am to 1st February 2023 at 3:00 pm